Distinct prevalence of the CYP19 Δ3(TTTA)7 allele in premenopausal versus postmenopausal breast cancer patients, but not in control individuals

European Journal of Cancer

Volumn 38, Issue 14, 2002, Pages 1911-1916

  Suspitsin, E N ^a   Grigoriev, M Y ^a   Togo, A V ^a   Kuligina, E S ^a   Belogubova, E V ^a   Pozharisski, K M ^a   Chagunava, O L ^b   Sokolov, E P ^c   Theillet, C ^d   Berstein, L M ^a   Hanson, K P ^a   Imyanitov, E N ^a  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^b Center of Mammology   (Russian Federation)

^c ZOOLOGICAL INSTITUTE   (Russian Federation)

^d INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

Author keywords

Breast cancer; CYP19; Menopause; Polymorphism; Predisposition

Indexed keywords

AROMATASE; CYTOCHROME P450; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROL; CONTROLLED STUDY; DATA ANALYSIS; DONOR; FEMALE; GENE DELETION; GENE INSERTION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC CODE; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; INTRON; MAJOR CLINICAL STUDY; MENOPAUSE; POSTMENOPAUSE; PREMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; RISK; RISK FACTOR; SILENCER GENE;

ADULT; AGED; AGED, 80 AND OVER; AROMATASE; BREAST NEOPLASMS; DNA, NEOPLASM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; POSTMENOPAUSE; PREMENOPAUSE; RISK FACTORS;

EID: 0036710934     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00149-1     Document Type: Article

References (27)

1. Weston A., Godbold J.H. Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Perspect. 105(Suppl 4):1997;919-926.
2. Dunning A.M., Healey C.S., Pharoah P.D., Teare M.D., Ponder B.A., Easton D.F. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 8:1999;843-854.
3. Kristensen V.N., Borresen-Dale A.L. Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism. Mutat Res. 462:2000;323-333.
4. Goldman R., Shields P.G. Molecular epidemiology of breast cancer. In Vivo. 12:1998;43-48.
5. Rebbeck T.R. Inherited genetic predisposition in breast cancer. A population-based perspective. Cancer. 86:1999;2493-2501.
6. Thompson P.A., Ambrosone C. Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. J Natl Cancer Inst Monog r. 27:2000;125-134.
7. Ries L.A.G., Kosary C.L., Hankey B.F., Harras A., Miller B.A., Edwards B.K. SEER Cancer Statistics Review, 1973-1993: Tables and Graphs. 1996;National Cancer Institute, Bethesda.
8. Chenevix-Trench G., Southall M., Kidson C. Restriction fragment length polymorphisms of L-myc and myb in human leukaemia and lymphoma in relation to age-selected controls. Br J Cancer. 60:1989;872-874.
9. Belogubova E.V., Togo A.V., Kondratieva T.V., Lemehov V.G., Hanson K.P., Imyanitov E.N. GSTM1 genotypes in elderly tumour-free smokers and non-smokers. Lung Cancer. 29:2000;189-195.
10. Kuligina E.S., Togo A.V., Suspitsin E.N.et al. CYP17 polymorphism in the groups of distinct breast cancer susceptibility: comparison of patients with the bilateral disease vs. monolateral breast cancer patients vs. middle-aged female controls vs. elderly tumour-free women. Cancer Lett. 156:2000;45-50.
11. Togo A.V., Suspitsin E.N., Grigoriev M.Y.et al. L-myc polymorphism in cancer patients, healthy blood donors and elderly, tumour-free individuals in Russia. Int J Cancer. 85:2000;747-750.
12. Miller W.R. Estrogen and Breast Cancer. 1996;RG Landes Co, Austin.
13. Santner S.J., Pauley R.J., Tait L., Kaseta J., Santen R.J. Aromatase activity and expression in breast cancer and benign breast tissue stromal cells. J Clin Endocrinol Metab. 82:1997;200-208.
14. Kristensen V.N., Andersen T.I., Lindblom A., Erikstein B., Magnus P., Borresen-Dale A.L. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics8. 43-48:1998.
15. Haiman C.A., Hankinson S.E., Spiegelman D.et al. A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk. Int J Cancer. 87:2000;204-210.
16. Healey C.S., Dunning A.M., Durocher F.et al. Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis. 21:2000;189-193.
17. Baxter S.W., Choong D.Y., Eccles D.M., Campbell I.G. Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis. 22:2001;347-349.
18. Probst-Hensch N.M., Ingles S.A., Diep A.T.et al. Aromatase and breast cancer susceptibility. Endocr Relat Cancer. 6:1999;165-173.
19. Siegelmann-Danieli N., Buetow K.H. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br J Cancer. 79:1999;456-463.
20. Kurosaki K., Saitoh H., Oota H., Watanabe Y., Kiuchi M., Ueda S. Combined polymorphism associated with a 3-bp deletion in the 5′-flanking region of a tetrameric short tandem repeat at the CYP19 locus. Jpn J Legal Med. 51:1997;191-195.
21. Mullenbach R., Lagoda P.J., Welter C. An efficient salt-chloroform extraction of DNA from blood and tissues. Trends Genet. 5:1989;391.
22. Breslow N.E., Day N.E. Statistical Methods in Cancer Research. IARC Scientific Publications, No. 32, Vol. 1: The Analysis of Case-control Studies. 1980;International Agency for Research on Cancer, Lyon.
23. Polymeropoulos M.H., Xiao H., Rath D.S., Merril C.R. Tetranucleotide repeat polymorphism at the human aromatase cytochrome P-450 gene (CYP19). Nucleic Acids Res. 19:1991;95.
24. Miyoshi Y., Iwao K., Ikeda N., Egawa C., Noguchi S. Breast cancer risk associated with polymorphism in CYP19 in Japanese women. Int J Cancer. 89:2000;325-328.
25. Sasano H., Harada N. Intratumoural aromatase in human breast, endometrial, and ovarian malignacies. Endocr Rev. 19:1998;593-607.
26. Key T.J., Wang D.Y., Brown J.B.et al. A prospective study of urinary oestrogen excretion and breast cancer risk. Br J Cancer. 73:1996;1615-1619.
27. Hilakivi-Clarke L. Estrogens, BRCA1, and breast cancer. Cancer Res. 60:2000;4993-5001.